Donna Flesher is Vice President of Biomarkers at HI-Bio. She has deep industry experience leading precision medicine strategies from discovery through development and commercialization.

Prior to joining HI-Bio, Donna was most recently the head of Oncology Clinical Biomarkers at Amgen, where she led a team accountable for the development and execution of biomarker strategies for a diverse portfolio of more than 25 therapeutic programs spanning both early and late-stage clinical development. Throughout her time at Amgen, Donna held numerous roles across discovery research, translational sciences, and clinical development. Before her time at Amgen, she completed a postdoctoral fellowship in biomarker discovery and human genetics in autoimmune disorders at Genentech. Donna received her PhD in Immunology from Stanford University.